The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Ibritumomab Tiuxetan Market Research Report 2025
Synopsis
It is the world's first radiolabeled monoclonal antibody, launched in the United States in 2002 and approved for the treatment of refractory and relapsed B-cell non-Hodgkin's lymphoma. Radioimmunization represented by Zevalin marks a new era for human treatment of non-Hodgkin lymphoma. Zevalin combines the excellent targeting of monoclonal antibodies and the powerful radiotherapy effect of radioisotopes, so it can maximize the effect of radiotherapy. kill tumor cells.
Highlights
The global Ibritumomab Tiuxetan market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The global market for Ibritumomab Tiuxetan in Follicular Non-hodgkin Lymphoma is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of Ibritumomab Tiuxetan include CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma and Kedrion, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, 0.05, which accounted for % of the global market of Ibritumomab Tiuxetan in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ibritumomab Tiuxetan, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ibritumomab Tiuxetan.
The Ibritumomab Tiuxetan market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Ibritumomab Tiuxetan market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ibritumomab Tiuxetan companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
CASI Pharmaceuticals
Biogen
Bayer
Spectrum
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Product Type Insights
Global markets are presented by Ibritumomab Tiuxetan type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Ibritumomab Tiuxetan are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Ibritumomab Tiuxetan segment by Concentration
0.05
0.25
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Ibritumomab Tiuxetan market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Ibritumomab Tiuxetan market.
Ibritumomab Tiuxetan Segment by Application
Follicular Non-hodgkin Lymphoma
Metastatic B-cell Non-hodgkin Lymphoma
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Ibritumomab Tiuxetan market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ibritumomab Tiuxetan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Ibritumomab Tiuxetan and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Ibritumomab Tiuxetan industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ibritumomab Tiuxetan.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ibritumomab Tiuxetan companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
It is the world's first radiolabeled monoclonal antibody, launched in the United States in 2002 and approved for the treatment of refractory and relapsed B-cell non-Hodgkin's lymphoma. Radioimmunization represented by Zevalin marks a new era for human treatment of non-Hodgkin lymphoma. Zevalin combines the excellent targeting of monoclonal antibodies and the powerful radiotherapy effect of radioisotopes, so it can maximize the effect of radiotherapy. kill tumor cells.
Highlights
The global Ibritumomab Tiuxetan market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Ibritumomab Tiuxetan is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The global market for Ibritumomab Tiuxetan in Follicular Non-hodgkin Lymphoma is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of Ibritumomab Tiuxetan include CASI Pharmaceuticals, Biogen, Bayer, Spectrum, CSL Behring, Grifols, Baxalta, Octapharma and Kedrion, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, 0.05, which accounted for % of the global market of Ibritumomab Tiuxetan in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ibritumomab Tiuxetan, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ibritumomab Tiuxetan.
The Ibritumomab Tiuxetan market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Ibritumomab Tiuxetan market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ibritumomab Tiuxetan companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
CASI Pharmaceuticals
Biogen
Bayer
Spectrum
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Product Type Insights
Global markets are presented by Ibritumomab Tiuxetan type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Ibritumomab Tiuxetan are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Ibritumomab Tiuxetan segment by Concentration
0.05
0.25
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Ibritumomab Tiuxetan market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Ibritumomab Tiuxetan market.
Ibritumomab Tiuxetan Segment by Application
Follicular Non-hodgkin Lymphoma
Metastatic B-cell Non-hodgkin Lymphoma
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Ibritumomab Tiuxetan market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ibritumomab Tiuxetan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Ibritumomab Tiuxetan and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Ibritumomab Tiuxetan industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ibritumomab Tiuxetan.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ibritumomab Tiuxetan companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Concentration
1.2.1 Global Ibritumomab Tiuxetan Market Size Growth Rate by Concentration: 2017 VS 2021 VS 2028
1.2.2 0.05
1.2.3 0.25
1.3 Market by Application
1.3.1 Global Ibritumomab Tiuxetan Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Follicular Non-hodgkin Lymphoma
1.3.3 Metastatic B-cell Non-hodgkin Lymphoma
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Ibritumomab Tiuxetan Market Perspective (2017-2028)
2.2 Ibritumomab Tiuxetan Growth Trends by Region
2.2.1 Ibritumomab Tiuxetan Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Ibritumomab Tiuxetan Historic Market Size by Region (2017-2022)
2.2.3 Ibritumomab Tiuxetan Forecasted Market Size by Region (2023-2028)
2.3 Ibritumomab Tiuxetan Market Dynamics
2.3.1 Ibritumomab Tiuxetan Industry Trends
2.3.2 Ibritumomab Tiuxetan Market Drivers
2.3.3 Ibritumomab Tiuxetan Market Challenges
2.3.4 Ibritumomab Tiuxetan Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ibritumomab Tiuxetan Players by Revenue
3.1.1 Global Top Ibritumomab Tiuxetan Players by Revenue (2017-2022)
3.1.2 Global Ibritumomab Tiuxetan Revenue Market Share by Players (2017-2022)
3.2 Global Ibritumomab Tiuxetan Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ibritumomab Tiuxetan Revenue
3.4 Global Ibritumomab Tiuxetan Market Concentration Ratio
3.4.1 Global Ibritumomab Tiuxetan Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ibritumomab Tiuxetan Revenue in 2021
3.5 Ibritumomab Tiuxetan Key Players Head office and Area Served
3.6 Key Players Ibritumomab Tiuxetan Product Solution and Service
3.7 Date of Enter into Ibritumomab Tiuxetan Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ibritumomab Tiuxetan Breakdown Data by Concentration
4.1 Global Ibritumomab Tiuxetan Historic Market Size by Concentration (2017-2022)
4.2 Global Ibritumomab Tiuxetan Forecasted Market Size by Concentration (2023-2028)
5 Ibritumomab Tiuxetan Breakdown Data by Application
5.1 Global Ibritumomab Tiuxetan Historic Market Size by Application (2017-2022)
5.2 Global Ibritumomab Tiuxetan Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Ibritumomab Tiuxetan Market Size (2017-2028)
6.2 North America Ibritumomab Tiuxetan Market Size by Country (2017-2022)
6.3 North America Ibritumomab Tiuxetan Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Ibritumomab Tiuxetan Market Size (2017-2028)
7.2 Europe Ibritumomab Tiuxetan Market Size by Country (2017-2022)
7.3 Europe Ibritumomab Tiuxetan Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ibritumomab Tiuxetan Market Size (2017-2028)
8.2 Asia-Pacific Ibritumomab Tiuxetan Market Size by Country (2017-2022)
8.3 Asia-Pacific Ibritumomab Tiuxetan Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Ibritumomab Tiuxetan Market Size (2017-2028)
9.2 Latin America Ibritumomab Tiuxetan Market Size by Country (2017-2022)
9.3 Latin America Ibritumomab Tiuxetan Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ibritumomab Tiuxetan Market Size (2017-2028)
10.2 Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2017-2022)
10.3 Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 CASI Pharmaceuticals
11.1.1 CASI Pharmaceuticals Company Detail
11.1.2 CASI Pharmaceuticals Business Overview
11.1.3 CASI Pharmaceuticals Ibritumomab Tiuxetan Introduction
11.1.4 CASI Pharmaceuticals Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.1.5 CASI Pharmaceuticals Recent Development
11.2 Biogen
11.2.1 Biogen Company Detail
11.2.2 Biogen Business Overview
11.2.3 Biogen Ibritumomab Tiuxetan Introduction
11.2.4 Biogen Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.2.5 Biogen Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Ibritumomab Tiuxetan Introduction
11.3.4 Bayer Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.3.5 Bayer Recent Development
11.4 Spectrum
11.4.1 Spectrum Company Detail
11.4.2 Spectrum Business Overview
11.4.3 Spectrum Ibritumomab Tiuxetan Introduction
11.4.4 Spectrum Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.4.5 Spectrum Recent Development
11.5 CSL Behring
11.5.1 CSL Behring Company Detail
11.5.2 CSL Behring Business Overview
11.5.3 CSL Behring Ibritumomab Tiuxetan Introduction
11.5.4 CSL Behring Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.5.5 CSL Behring Recent Development
11.6 Grifols
11.6.1 Grifols Company Detail
11.6.2 Grifols Business Overview
11.6.3 Grifols Ibritumomab Tiuxetan Introduction
11.6.4 Grifols Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.6.5 Grifols Recent Development
11.7 Baxalta
11.7.1 Baxalta Company Detail
11.7.2 Baxalta Business Overview
11.7.3 Baxalta Ibritumomab Tiuxetan Introduction
11.7.4 Baxalta Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.7.5 Baxalta Recent Development
11.8 Octapharma
11.8.1 Octapharma Company Detail
11.8.2 Octapharma Business Overview
11.8.3 Octapharma Ibritumomab Tiuxetan Introduction
11.8.4 Octapharma Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.8.5 Octapharma Recent Development
11.9 Kedrion
11.9.1 Kedrion Company Detail
11.9.2 Kedrion Business Overview
11.9.3 Kedrion Ibritumomab Tiuxetan Introduction
11.9.4 Kedrion Revenue in Ibritumomab Tiuxetan Business (2017-2022)
11.9.5 Kedrion Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Ibritumomab Tiuxetan Market Size Growth Rate by Concentration (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of 0.05
Table 3. Key Players of 0.25
Table 4. Global Ibritumomab Tiuxetan Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 5. Global Ibritumomab Tiuxetan Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Ibritumomab Tiuxetan Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Ibritumomab Tiuxetan Market Share by Region (2017-2022)
Table 8. Global Ibritumomab Tiuxetan Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Ibritumomab Tiuxetan Market Share by Region (2023-2028)
Table 10. Ibritumomab Tiuxetan Market Trends
Table 11. Ibritumomab Tiuxetan Market Drivers
Table 12. Ibritumomab Tiuxetan Market Challenges
Table 13. Ibritumomab Tiuxetan Market Restraints
Table 14. Global Ibritumomab Tiuxetan Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Ibritumomab Tiuxetan Market Share by Players (2017-2022)
Table 16. Global Top Ibritumomab Tiuxetan Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ibritumomab Tiuxetan as of 2021)
Table 17. Ranking of Global Top Ibritumomab Tiuxetan Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Ibritumomab Tiuxetan Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Ibritumomab Tiuxetan Product Solution and Service
Table 21. Date of Enter into Ibritumomab Tiuxetan Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Ibritumomab Tiuxetan Market Size by Concentration (2017-2022) & (US$ Million)
Table 24. Global Ibritumomab Tiuxetan Revenue Market Share by Concentration (2017-2022)
Table 25. Global Ibritumomab Tiuxetan Forecasted Market Size by Concentration (2023-2028) & (US$ Million)
Table 26. Global Ibritumomab Tiuxetan Revenue Market Share by Concentration (2023-2028)
Table 27. Global Ibritumomab Tiuxetan Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Ibritumomab Tiuxetan Revenue Market Share by Application (2017-2022)
Table 29. Global Ibritumomab Tiuxetan Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Ibritumomab Tiuxetan Revenue Market Share by Application (2023-2028)
Table 31. North America Ibritumomab Tiuxetan Market Size by Country (2017-2022) & (US$ Million)
Table 32. North America Ibritumomab Tiuxetan Market Size by Country (2023-2028) & (US$ Million)
Table 33. Europe Ibritumomab Tiuxetan Market Size by Country (2017-2022) & (US$ Million)
Table 34. Europe Ibritumomab Tiuxetan Market Size by Country (2023-2028) & (US$ Million)
Table 35. Asia-Pacific Ibritumomab Tiuxetan Market Size by Region (2017-2022) & (US$ Million)
Table 36. Asia-Pacific Ibritumomab Tiuxetan Market Size by Region (2023-2028) & (US$ Million)
Table 37. Latin America Ibritumomab Tiuxetan Market Size by Country (2017-2022) & (US$ Million)
Table 38. Latin America Ibritumomab Tiuxetan Market Size by Country (2023-2028) & (US$ Million)
Table 39. Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2017-2022) & (US$ Million)
Table 40. Middle East & Africa Ibritumomab Tiuxetan Market Size by Country (2023-2028) & (US$ Million)
Table 41. CASI Pharmaceuticals Company Detail
Table 42. CASI Pharmaceuticals Business Overview
Table 43. CASI Pharmaceuticals Ibritumomab Tiuxetan Product
Table 44. CASI Pharmaceuticals Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 45. CASI Pharmaceuticals Recent Development
Table 46. Biogen Company Detail
Table 47. Biogen Business Overview
Table 48. Biogen Ibritumomab Tiuxetan Product
Table 49. Biogen Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 50. Biogen Recent Development
Table 51. Bayer Company Detail
Table 52. Bayer Business Overview
Table 53. Bayer Ibritumomab Tiuxetan Product
Table 54. Bayer Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 55. Bayer Recent Development
Table 56. Spectrum Company Detail
Table 57. Spectrum Business Overview
Table 58. Spectrum Ibritumomab Tiuxetan Product
Table 59. Spectrum Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 60. Spectrum Recent Development
Table 61. CSL Behring Company Detail
Table 62. CSL Behring Business Overview
Table 63. CSL Behring Ibritumomab Tiuxetan Product
Table 64. CSL Behring Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 65. CSL Behring Recent Development
Table 66. Grifols Company Detail
Table 67. Grifols Business Overview
Table 68. Grifols Ibritumomab Tiuxetan Product
Table 69. Grifols Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 70. Grifols Recent Development
Table 71. Baxalta Company Detail
Table 72. Baxalta Business Overview
Table 73. Baxalta Ibritumomab Tiuxetan Product
Table 74. Baxalta Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 75. Baxalta Recent Development
Table 76. Octapharma Company Detail
Table 77. Octapharma Business Overview
Table 78. Octapharma Ibritumomab Tiuxetan Product
Table 79. Octapharma Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 80. Octapharma Recent Development
Table 81. Kedrion Company Detail
Table 82. Kedrion Business Overview
Table 83. Kedrion Ibritumomab Tiuxetan Product
Table 84. Kedrion Revenue in Ibritumomab Tiuxetan Business (2017-2022) & (US$ Million)
Table 85. Kedrion Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ibritumomab Tiuxetan Market Share by Concentration: 2021 VS 2028
Figure 2. 0.05 Features
Figure 3. 0.25 Features
Figure 4. Global Ibritumomab Tiuxetan Market Share by Application in 2021 & 2028
Figure 5. Follicular Non-hodgkin Lymphoma Case Studies
Figure 6. Metastatic B-cell Non-hodgkin Lymphoma Case Studies
Figure 7. Ibritumomab Tiuxetan Report Years Considered
Figure 8. Global Ibritumomab Tiuxetan Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 9. Global Ibritumomab Tiuxetan Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Ibritumomab Tiuxetan Market Share by Region: 2021 VS 2028
Figure 11. Global Ibritumomab Tiuxetan Market Share by Players in 2021
Figure 12. Global Top Ibritumomab Tiuxetan Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ibritumomab Tiuxetan as of 2021)
Figure 13. The Top 10 and 5 Players Market Share by Ibritumomab Tiuxetan Revenue in 2021
Figure 14. North America Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 15. North America Ibritumomab Tiuxetan Market Share by Country (2017-2028)
Figure 16. United States Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. Canada Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. Europe Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Europe Ibritumomab Tiuxetan Market Share by Country (2017-2028)
Figure 20. Germany Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. France Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. U.K. Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Italy Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Russia Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Nordic Countries Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Asia-Pacific Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Ibritumomab Tiuxetan Market Share by Region (2017-2028)
Figure 28. China Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Japan Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. South Korea Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Southeast Asia Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. India Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Australia Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Latin America Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Latin America Ibritumomab Tiuxetan Market Share by Country (2017-2028)
Figure 36. Mexico Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Brazil Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Middle East & Africa Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Middle East & Africa Ibritumomab Tiuxetan Market Share by Country (2017-2028)
Figure 40. Turkey Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Saudi Arabia Ibritumomab Tiuxetan Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. CASI Pharmaceuticals Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 43. Biogen Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 44. Bayer Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 45. Spectrum Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 46. CSL Behring Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 47. Grifols Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 48. Baxalta Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 49. Octapharma Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 50. Kedrion Revenue Growth Rate in Ibritumomab Tiuxetan Business (2017-2022)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
